



National Center
for Advancing
Translational Sciences

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**3rd Joint Meeting of the
National Center for Advancing Translational Sciences Advisory Council
and Cures Acceleration Network Review Board**

May 17, 2013

8:30 a.m. - 5:00 p.m.

Building 31C, 6th Floor, Conference Room 6
Bethesda, Maryland 20892

FUTURE COUNCIL and CAN BOARD MEETINGS	
2013	2014
September 16	January 16
	May 16
	September 19
	<u>CAN Board only</u>
December 12	December 11

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to: <http://videocast.nih.gov/summary.asp?live=12737>

8:30 - 8:50 a.m.

CALL TO ORDER, OPEN SESSION

Christopher P. Austin, M.D.
Director, NCATS
Chairperson – Advisory Council

Freda Lewis-Hall, M.D.
Chief Medical Officer, Pfizer
Chairperson – CAN Board

8:50 - 9:00 a.m.

Approval of Minutes of 2nd Joint Meeting

**Confirmation of Dates for Future NCATS Advisory Council/CAN
Review Board Meetings**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

9:00 - 10:00 a.m.

NCATS DIRECTOR'S REPORT

Presenter: Christopher P. Austin, M.D., Director, NCATS

Discussion

10:00 - 10:30 a.m.

BREAK

10:30 - 11:30 a.m.

REPORT FROM THE CAN REVIEW BOARD SUB-COMMITTEE

Presenter: Freda Lewis-Hall, M.D., Chief Medical Officer, Pfizer

CAN Subcommittee Members

Pamela B. Davis, M.D., Ph.D.

Geoffrey S. Ginsburg, M.D., Ph.D.

Bernard H. Munos, M.B.A.

Discussion

11:30 a.m. - 12:30 p.m.

NIH INCLUSION POLICY

Presenters: Meredith D. Temple-O'Connor, Ph.D., NIH Inclusion Policy Officer, Office of Extramural Research, Office of the Director

Janine Clayton, M.D., Director, Office of Research on Women's Health, Office of the Director

Discussion

12:30 - 1:30 p.m.

LUNCH

1:30 - 2:30 p.m.

CONCEPT CLEARANCE OF PROPOSED INITIATIVES

Presenter: Lili Portilla, M.P.A., Acting Director, Office of Policy, Communications & Strategic Alliances, NCATS

SBIR Topics:

- Development of neurocognitive pediatric tools for measuring and analyzing clinical study endpoints in rare neurocognitive disorders
- Development of biomarkers for rare diseases as endpoints for clinical trial measurements
- Portable parathyroid hormone pump and calcium-monitoring device
- Development of improved genome-editing technologies
- Development of droplet detection system for HTS
- Platforms for the rapid development of cell-based assays for rare diseases

Discussion

2:30 p.m.

ADJOURN, OPEN SESSION

2:45 p.m. - 5:00 p.m.

CLOSED SESSION

This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

Review of Conflict of Interest, Confidentiality, and Council Procedures

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

Council Consideration of Pending Applications

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council